Opus Genetics, Inc. (IRD:NASDAQ) closed at $3.99 on November 20, 2026, down 2.21% on the day. The stock trades 43.6% below its 52-week high of $7.07 and 114.5% above its 52-week low of $1.86. Over the past year, it gained 99.5%. Opus Genetics, Inc. is part of the Health Care sector.
In 252 trading sessions since November 20, 2025, IRD closed higher on 131 days (52%). Its best day was September 9, 2026 (+32.03%) and its worst was June 5, 2026 (-13.15%). The stock moved 10% or more in a single session 10 times. It opened at least 5% above the previous day's high 2 times.
Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire's pipeline includes two small molecular product candidates targeting front and back of the eye indications. The Nyxol candidate is being developed for dim light or night vision disturbances, reversal of pharmacologically induced mydriasis, and presbyopia. The second product candidate, APX3330, is being developed for diabetic retinopathy and diabetic macular edema.
Find more stocks like IRD with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.